US pharma giant Merck & Co has announced the discontinuation of the clinical development programs for vibostolimab, an ...

Out with the old, in with the new. The end of the year in biopharma is typically marked by pipeline clear outs, and 2024 is ...

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors should consider ...

One LAG-3 drug has reached the market, namely Bristol-Myers Squibb's Opdualag, which combines its PD-1 inhibitor Opdivo ...

The company is scrapping two drugs aimed at targets called TIGIT and LAG-3, both of which were in the middle of Phase 3 ...

Teos' Phase II trial for inupadenant met its primary and secondary endpoints but offered little more than existing treatments ...

Merck, known as MSD outside of the United States and Canada, announced the discontinuation of the clinical development programmes for vibostolimab, an anti-TIGIT antibody, and favezelimab, an anti-LAG ...

Merck discontinues TIGIT drug vibostolimab and LAG-3 drug favezelimab after Phase 3 failures with Keytruda in lung cancer and ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

Teos Therapeutics has potential lung cancer treatment despite issues and strong financial position. Read here to know why we ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Arcus Biosciences specializes in the development of cancer immunotherapies, with a particular focus on its HIF2alpha and TIGIT programs. The company's market capitalization stands at $1.47 billion ...